ClinicalTrials.gg
RecruitingNCT07377578Updated Feb 6, 2026

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

A Phase 3 interventional study of Rocbrutinib and Ibrutinib in Mantle Cell Lymphoma, sponsored by Guangzhou Lupeng Pharmaceutical Company LTD.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Guangzhou Lupeng Pharmaceutical Company LTD. (part of Lupeng Pharmaceutical Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
394
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Lymphoma, Mantle-Cell with a site in China — 44 open to participants now, 56 under way, 10 of them phase 3. Lymphoma, Mantle-Cell · China.

Planned enrollment
11th of 91
394 · median 50
Started
2026
with 9 others
Phase 3
15 of 98
6 open now
Primary completion
2031-05
later than 51 of 55 live
Registered
89th of 98
by date
Lead sponsor
4 of 98
Guangzhou Lupeng Pharmaceutical Company LTD.

Among the 98 studies in Lymphoma, Mantle-Cell with a site in China, this one is the 11th largest by planned enrollment of the 91 interventional ones that give a count, is one of 10 that started in 2026, is one of 15 in phase 3, reaches primary completion later than 51 of the 55 other live ones, and was the 89th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

44 of the 98 studies in Lymphoma, Mantle-Cell with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Lymphoma, Mantle-Cell with a site in China, or all of them as a file.
02

Study summary

Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits both covalent (irreversible) and non-covalent (reversible) binding. This unique dual mechanism of action has shown promising efficacy and a favorable safety profile across various B-cell NHL subtypes in prior Phase 1 and 2 studies. This is a Phase 3, randomized, open-label study comparing Rocbrutinib versus investigator's choice of BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or orelabrutinib) in patients with MCL who have received at least one prior line of therapy and are naïve to BTK inhibitor treatment (except for intolerance).

03

Conditions studied

  • Mantle Cell Lymphoma

Keywords

  • Mantle Cell Lymphoma
  • BTK inhibitor
  • Rocbrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with MCL, who have received at least one prior systemic regimen(s), and have experienced disease progression on the most recent .
  • Have at least one according to the Lugano Response Criteria 2014.
  • (ECOG) Performance Status score of 0-2.
  • ≥ 12 weeks.
  • Adequate coagulation function, liver and kidney function, bone marrow hematopoietic function, etc.
  • Toxicities or complications from prior anti-tumor therapy have recovered to Grade ≤1 according to v5.0.
  • All male subjects and female subjects of must strictly use medically approved throughout the entire study period. All male subjects must also avoid sperm donation during the above period. For women of childbearing potential, the result of serum pregnancy test must be obtained. Women must be non-lactating.
  • Subject voluntarily enrolls and signs the form, and agrees to comply with the study treatment plan and visit schedule.

Exclusion criteria

Exclusion Criteria:

  • to Rocbrutinib or any study drug in the control group.
  • Prior treatment with any BTK-targeted therapy (except for intolerance).
  • Central nervous system (CNS) involvement by lymphoma.
  • History of other (except MCL) within the past 2 years, excluding radically cured skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, localized squamous cell carcinoma, etc.
  • History of major cardiovascular events within 6 months prior to randomization.
  • Presence of any severe and/or uncontrolled systemic disease that, in the investigator's judgment, or have poor cardiac function.
  • Uncontrolled active bacterial, fungal, or viral systemic infection, or active tuberculosis infection.
  • Any medical condition that could interfere with the absorption, distribution, metabolism, or excretion (ADME) of the drug or the evaluation of study outcomes.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
394 participants (estimated)

Study arms

  • Experimental
    Arm A (Rocbrutinib)

    Drug: Rocbrutinib

  • Active comparator
    Arm B (ibrutinib, acalabrutinib, zanubrutinib, or orelabrutinib)

    Drug: Ibrutinib · Drug: Acalabrutinib · Drug: Zanubrutinib · Drug: Orelabrutinib

Interventions

  • Rocbrutinib at 150 mg once daily orally until disease progression or unacceptable toxicity

  • Ibrutinib, 560 mg once daily orally and continuously

  • Acalabrutinib, 100 mg twice daily orally and continuously

  • Zanubrutinib, 160 mg twice daily orally and continuously

  • Orelabrutinib, 150 mg once daily orally and continuously

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by IRC

    Time frame: approximately 30 months

Secondary outcomes

  1. PFS assessed by INV

    Time frame: approximately 30 months

  2. Overall Response Rate (ORR) assessed by IRC and INV, respectively

    Time frame: Up to approximately 24 months

  3. Duration of Response (DOR) assessed by IRC and INV, respectively

    Time frame: approximately 30 months

  4. Overall Survival

    Time frame: approximately 40 months

  5. Number of participants with treatment-emergent adverse event as assessed by CTCAE v5.0

    Time frame: Up to approximately 40 months

  6. Number of participants with treatment-related adverse event as assessed by CTCAE v5.0

    Time frame: Up to approximately 40 months

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2031, 63 months after the start.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's planned 63 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 30, 2026
StartActual
Feb 5, 2026
Primary completionEst.
May 30, 2031
CompletionEst.
Jan 30, 2033
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07377578
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Feb 5, 2026
Primary completion
May 30, 2031 (estimated)
Completion
Jan 30, 2033 (estimated)
Last update
Feb 6, 2026

Study contacts

Yuqin Song
Contact
SongYQ_VIP@163.com
+86-010-88196118

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocbrutinib

Start the discussion